All-trans Retinoic Acid With Daunorubicin Or Idarubicin For Risk-adapted Treatment Of Acute Promyelocytic Leukaemia: A Matched-pair Analysis Of The Pethema Lpa-2005 And Ic-apl Studies

dc.creatorSanz
dc.creatorMiguel A.; Montesinos
dc.creatorPau; Kim
dc.creatorHaesook T.; Ruiz-Argueelles
dc.creatorGuillermo J.; Undurraga
dc.creatorMaria S.; Uriarte
dc.creatorMaria R.; Martinez
dc.creatorLem; Jacomo
dc.creatorRafael H.; Gutierrez-Aguirre
dc.creatorHomero; Melo
dc.creatorRaul A. M.; Bittencourt
dc.creatorRosane; Pasquini
dc.creatorRicardo; Pagnano
dc.creatorKatia; Fagundes
dc.creatorEvandro M.; Vellenga
dc.creatorEdo; Holowiecka
dc.creatorAlexandra; Gonzalez-Huerta
dc.creatorAna J.; Fernandez
dc.creatorPascual; De la Serna
dc.creatorJavier; Brunet
dc.creatorSalut; De Lisa
dc.creatorElena; Gonzalez-Campos
dc.creatorJose; Ribera
dc.creatorJose M.; Krsnik
dc.creatorIsabel; Ganser
dc.creatorArnold; Berliner
dc.creatorNancy; Ribeiro
dc.creatorRaul C.; Lo-Coco
dc.creatorFrancesco; Lowenberg
dc.creatorBob; Rego
dc.creatorEduardo M.
dc.date2015-AUG
dc.date2016-06-07T13:34:38Z
dc.date2016-06-07T13:34:38Z
dc.date.accessioned2018-03-29T01:50:15Z
dc.date.available2018-03-29T01:50:15Z
dc.identifier
dc.identifierAll-trans Retinoic Acid With Daunorubicin Or Idarubicin For Risk-adapted Treatment Of Acute Promyelocytic Leukaemia: A Matched-pair Analysis Of The Pethema Lpa-2005 And Ic-apl Studies. Springer, v. 94, p. 1347-1356 AUG-2015.
dc.identifier0939-5555
dc.identifierWOS:000357279200011
dc.identifier10.1007/s00277-015-2393-0
dc.identifierhttp://link.springer.com/article/10.1007%2Fs00277-015-2393-0
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/243954
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1307652
dc.descriptionFront-line treatment of acute promyelocytic leukaemia (APL) consists of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. In this setting, a comparison of idarubicin and daunorubicin has never been carried out. Two similar clinical trials using ATRA and chemotherapy for newly diagnosed APL were compared using matched-pair analysis. One was conducted by the PETHEMA/HOVON group with idarubicin and the other by the International Consortium on APL (IC-APL) using daunorubicin. Three hundred and fifty patients from the PETHEMA/HOVON cohort were matched with 175 patients in the IC-APL cohort, adjusting for the significantly unbalanced presenting features of the two entire cohorts. Complete remission (CR) rate was significantly higher in the PETHEMA/HOVON (94 %) than in the IC-APL cohort (85 %) (P = 0.002). The distribution of causes of induction failure and the time to achieve CR were similar in both cohorts. Patients who achieved CR had comparable cumulative incidence of relapse and disease-free survival rates, but lower overall and event-free survivals were observed in the IC-APL cohort, which was mainly due to a higher death rate during induction therapy. A higher death rate during consolidation therapy was also observed in the IC-APL. These results show that daunorubicin and idarubicin have similar antileukaemic efficacy in terms of primary resistance, molecular persistence, as well as molecular and haematological relapse rates when combined with ATRA in treatment of APL. However, a higher toxic death rate during induction and consolidation therapy was observed in the IC-APL cohort. This trial was registered at as #NCT00408278 [ClinicalTrials.gov].
dc.description94
dc.description8
dc.description
dc.description1347
dc.description1356
dc.descriptionInstituto de Salud Carlos III [RD12/0036/014]
dc.descriptionEuropean Regional Development Fund [RD12/0036/014]
dc.descriptionAmerican Society of Hematology
dc.descriptionFondazione Umberto Veronesi
dc.descriptionRoche South Arabia
dc.descriptionFundacao de Apoio a Pesquisa do Estado de Sao Paulo [1998/14247-6]
dc.descriptionFundacion Mexicana para la Salud
dc.descriptionSt. Jude Children's Research Hospital
dc.description
dc.description
dc.description
dc.languageen
dc.publisherSPRINGER
dc.publisher
dc.publisherNEW YORK
dc.relationANNALS OF HEMATOLOGY
dc.rightsfechado
dc.sourceWOS
dc.subjectAgent Arsenic Trioxide
dc.subjectResponse Criteria
dc.subjectTherapy
dc.subjectAnthracycline
dc.subjectConsolidation
dc.subjectOutcomes
dc.titleAll-trans Retinoic Acid With Daunorubicin Or Idarubicin For Risk-adapted Treatment Of Acute Promyelocytic Leukaemia: A Matched-pair Analysis Of The Pethema Lpa-2005 And Ic-apl Studies
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución